The phase Ib KEYNOTE-028 and phase II KEYNOTE-158 trials, whereas pembrolizumab resulted in durable, high response rates of 40% in previously treated, advanced non-colorectal, MSI-high/MMR-deficient cancer patients, included 22 (9.4%) cholangiocarcinoma cases and retrospectively evaluated PD-L1 status [153]. This evidence concerns the gene CD274 and cancer.